288 related articles for article (PubMed ID: 18614401)
1. The six questions of pathogen reduction technology: an overview of current opinions.
Solheim BG; Seghatchian J
Transfus Apher Sci; 2008 Aug; 39(1):51-7. PubMed ID: 18614401
[TBL] [Abstract][Full Text] [Related]
2. Update on pathogen reduction technology for therapeutic plasma: an overview.
Solheim BG; Seghatchian J
Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
[TBL] [Abstract][Full Text] [Related]
3. Current opinions on the role of pathogen reduction technology in improving the viral safety of blood and derivatives.
Seghatchian J
Transfus Apher Sci; 2008 Aug; 39(1):49-50. PubMed ID: 18617442
[No Abstract] [Full Text] [Related]
4. Pathogen reduction of blood components.
Solheim BG
Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
[TBL] [Abstract][Full Text] [Related]
5. Pathogen-reduction systems for blood components: the current position and future trends.
Seghatchian J; de Sousa G
Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
[TBL] [Abstract][Full Text] [Related]
6. Pathogen reduction technology.
Rock G
Transfus Apher Sci; 2008 Aug; 39(1):1. PubMed ID: 18619904
[No Abstract] [Full Text] [Related]
7. Alternative strategies in assuring blood safety: An overview.
Epstein JS
Biologicals; 2010 Jan; 38(1):31-5. PubMed ID: 20110174
[TBL] [Abstract][Full Text] [Related]
8. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment.
Svae TE; Neisser-Svae A; Bailey A; Reichl H; Biesert L; Schmidt T; Heger A; Römisch J
Transfus Apher Sci; 2008 Aug; 39(1):59-67. PubMed ID: 18619902
[TBL] [Abstract][Full Text] [Related]
9. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends.
Goodrich RP; Edrich RA; Li J; Seghatchian J
Transfus Apher Sci; 2006 Aug; 35(1):5-17. PubMed ID: 16935562
[TBL] [Abstract][Full Text] [Related]
10. Blood component therapy.
Fasano R; Luban NL
Pediatr Clin North Am; 2008 Apr; 55(2):421-45, ix. PubMed ID: 18381094
[TBL] [Abstract][Full Text] [Related]
11. Multilayer-strategy to enhance optimal safety of the blood supply: The role of pathogen inactivation for optimizing recipient safety and helping health care cost containment: Moderator views.
Seghatchian J
Transfus Apher Sci; 2015 Apr; 52(2):233-6. PubMed ID: 25748230
[TBL] [Abstract][Full Text] [Related]
12. TRALI risk reduction: donor and component management strategies.
Eder AF; Benjamin RJ
J Clin Apher; 2009; 24(3):122-9. PubMed ID: 19365816
[TBL] [Abstract][Full Text] [Related]
13. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light.
Cardo LJ; Salata J; Mendez J; Reddy H; Goodrich R
Transfus Apher Sci; 2007 Oct; 37(2):131-7. PubMed ID: 17950672
[TBL] [Abstract][Full Text] [Related]
14. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop.
Klein HG; Glynn SA; Ness PM; Blajchman MA;
Transfusion; 2009 Jun; 49(6):1262-8. PubMed ID: 19392769
[TBL] [Abstract][Full Text] [Related]
15. Quality assurance of the donor questionnaire and donor interview: a three year experience with an electronic donor questionnaire.
Flesland O; Seghatchian J
Transfus Apher Sci; 2009 Oct; 41(2):151-3. PubMed ID: 19683475
[TBL] [Abstract][Full Text] [Related]
16. Current issues in transfusion medicine in Norway.
Flesland O; Seghatchian J
Transfus Apher Sci; 2005 Feb; 32(1):7-10. PubMed ID: 15737866
[TBL] [Abstract][Full Text] [Related]
17. Pathogen reduction technology: methods, status of clinical trials, and future prospects.
Corash L
Curr Hematol Rep; 2003 Nov; 2(6):495-502. PubMed ID: 14561394
[TBL] [Abstract][Full Text] [Related]
18. Preparation of blood products for transfusion: is there a best method?
Devine DV; Serrano K
Biologicals; 2012 May; 40(3):187-90. PubMed ID: 22119012
[TBL] [Abstract][Full Text] [Related]
19. Reasons for moving toward a patient-centric paradigm of clinical transfusion medicine practice.
Vamvakas EC
Transfusion; 2013 Apr; 53(4):888-901. PubMed ID: 22882177
[TBL] [Abstract][Full Text] [Related]
20. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products.
Goodrich RP; Doane S; Reddy HL
Biologicals; 2010 Jan; 38(1):20-30. PubMed ID: 20093041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
